NASDAQ:MEDPMedpace Stock Price, Forecast & News

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MEDP shares have increased by 19.9% and is now trading at $100.26. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Medpace.

Medpace is scheduled to release its next quarterly earnings announcement on Monday, July 27th 2020. View our earnings forecast for Medpace.

Medpace will be holding an earnings conference call on Monday, July 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Medpace Holdings Inc (NASDAQ:MEDP) announced its quarterly earnings data on Tuesday, April, 28th. The company reported $0.76 earnings per share for the quarter, missing the consensus estimate of $0.77 by $0.01. The company had revenue of $230.88 million for the quarter, compared to analysts' expectations of $226.23 million. Medpace had a net margin of 12.37% and a return on equity of 17.18%. The business's revenue was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.64 earnings per share. View Medpace's earnings history.

5 equities research analysts have issued 1-year price targets for Medpace's stock. Their forecasts range from $75.00 to $99.00. On average, they anticipate Medpace's share price to reach $87.50 in the next year. This suggests that the stock has a possible downside of 12.7%. View analysts' price targets for Medpace.

News articles about MEDP stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medpace earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Medpace.

Some companies that are related to Medpace include EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS) and Auxly Cannabis Group (CBWTF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Baidu (BIDU), Alibaba Group (BABA), Square (SQ), JD.Com (JD), Trade Desk (TTD), Adobe (ADBE), Alteryx (AYX) and Cisco Systems (CSCO).

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.10%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View institutional ownership trends for Medpace.

MEDP stock was purchased by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $100.26.

Medpace has a market capitalization of $3.55 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe.

The official website for Medpace is www.medpace.com.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]